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1. Introduction
1.1. Epidemiology of chronic degenerative diseases in Mexico and the world
During the last 30 years relevant changes in the public health field have arisen worldwide,
among which the most representative are observed in developed countries where a big deal
of infectious diseases have been reduced and controlled as a result of the creation and intro‐
duction of powerful antibiotics [1].
In countries such as Australia, Austria, Belgium, Canada, Denmark, Finland, France, Ger‐
many,  Greece,  Ireland,  Italy,  Japan,  Luxembourg,  Netherlands,  New  Zealand,  Norway,
Portugal, Spain, Sweden, Switzerland, the United Kingdom, and the United States, incor‐
porated to the OECD (Organization for Economic Cooperation and Development), mortal‐
ity due to those diseases has diminished up to 38% in people between 35 and 69 years
old. Likewise, the risk of mortality before age 70 has diminished up to the 23%. Those re‐
ductions  have  been  the  result  of  social  changes  and  of  the  improvement  of  preventive
methods of infectious diseases. However, in recent years the prevalence of chronic degen‐
erative diseases has increased [1].
© 2013 Madrigal-Santillán et al.; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Chronic degenerative diseases (CDDs) represent a problem of public health for they have
become the cause of death worldwide both in adolescents and adults. Among the most
prevalent CDDs worldwide is obesity, the cardiovascular diseases (such as hypertension,
atherosclerosis), heart diseases, diabetes, chronic respiratory diseases, and cancer; which
have caused the 60% of the 58 million yearly deaths, which are approximately 35 million
people death for these diseases between 2005 and 2007 [2].
Prevalence in  chronic  degenerative  diseases  results  from different  factors,  among which
the technologic advance and modernization affect life styles where an increase in process‐
ed foods consumption with a high level  of  fat  content,  a  sedentary lifestyle since child‐
hood, alcohol and tobacco, stress and a lack of culture in terms of damage prevention and
health risks [1,2].
Mexico does not escape this situation as a result of specific factors to our country such as
economic development, concentration of population in urban areas, lack of support to im‐
prove the health services and the limitations in preventive programs, particularly in the
population under 10 years. Besides, there is a transformation of the population pyramid
due to a reduction in mortality and a decrease in birth rate; both phenomena are identi‐
fied as epidemiologic and demographic transitions [2]. In México, the morbidity data pro‐
duced by the CDDs are taken from the statistics of the healthcare sector and published by
the healthcare ministry. Although in those reports not all the existing cases are included
(not all patients request healthcare services), they are a good help to understand the dam‐
age behavior along with other indicators of prevalence that estimate the number of cases
in the population within a specific period of time. Such indicators are obtained from the
national healthcare survey and from the national healthcare and nutrition survey 2006 [2].
On the other hand, the mortality statistics are considered as more reliable due to the per‐
manent job in updating the database. The information is obtained from the records of the
national institute of statistics, geography and informatics (INEGI) and the general bureau
of health information,  in conjunction with the epidemiological  AVAD index,  which is  a
measure that combines years of healthy life lost due to premature mortality and years of
life lost due to disability [3].
As mentioned above, the epidemiological and demographic transitions are important factors
for the prevalence of chronic degenerative diseases and indicate changes in the behavior of
population dynamics, as well as damage to health which are the result of the low socioeco‐
nomic development and the impact of government policies on public health. The demo‐
graphic transition shows the change in a steady state population with high fertility and
mortality associated with the low socioeconomic development process and/or moderniza‐
tion. This process is irreversible and was constructed from the first countries reaching socio-
economic development in Europe such as France and England. In recent years it has made
rapid changes affecting the world population [2].
According to data from INEGI and the national population council (CONAPO), Mexico has
experienced an accelerated process of demographic transition, which has influenced the eco‐
nomic development and migration, leading to a reduction in mortality and a parallel high
birth rates, as well as the consequent population growth, so it is estimated that between 2010
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and 2050 the proportion of elderly people in Mexico will grow from 7% to 28% and with it
the possibility of an chronic degenerative disease is greater [2,3].
In the case of the epidemiological transition, this is characterized by a reduction of morbidi‐
ty and mortality from transmissible diseases and an increase in chronic degenerative diseas‐
es. In recent years, this parameter has shown that in both developed and developing
countries, the proportion of infectious diseases in individuals over age 15 is stable, but un‐
fortunately the CDDs are increasing, showing that they occupy almost half of value of mor‐
bility globally. A relevant fact is observed in developed countries (like France, Germany,
Japan, United Kingdom, and United States) where the greatest impact of transmissible dis‐
eases remains the HIV/AIDS; but the cerebrovascular diseases and the ischemic heart dis‐
ease are among the main causes of morbidity and mortality (Table 1) in individuals over age
15, both diseases represent more than 36% of deaths worldwide [2].
In the specific case of Mexico, it is well-known that infectious diseases made up the profile
of mortality in the fifties, since half of the deaths were caused by diarrhea and respiratory
infections, for reproductive problems and associated malnutrition conditions. Nowadays,
these diseases (classified as lag diseases) are concentrated in less than 15% of deaths [2].
In the last 10 years, there has been an overlap between lag diseases and the so-called emerg‐
ing diseases. Thus, the epidemiological transition has ranked the chronic degenerative dis‐
eases among the 10 leading causes of death, highlighting the type 2 diabetes, obesity,
cardiovascular diseases, malignant neoplasms and cerebrovascular diseases [4].
Mortality
(individuals between 15 and 50 years)
Mortality
(over 60 years)
Cause Deaths
(thousands)
Cause Deaths
(thousands)
1 HIV / AIDS 2279 1 Ischemic heart disease 5825
2 Ischemic heart disease 1332 2 Cerebrovascular diseases 4689
3 Tuberculosis 1036 3 Chronic obstructive pulmonary
disease
2399
4 Injuries from traffic accidents 814 4 Infections of lower respiratory 1396
5 Cerebrovascular diseases 783 5 Trachea and lung cancer 928
6 Self-harm 672 6 Diabetes 754
7 Violence 473 7 Hypertensive heart disease 735
8 Liver cirrhosis 382 8 Stomach Cancer 605
9 Infections of lower respiratory 352 9 Tuberculosis 495
10 Chronic obstructive pulmonary
disease
343 10 Colorectal cancer 477
Table 1. Leading causes of death in people over 15 years in the world (as a function of AVAD index)
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2. Definition, importance and control of oxidative stress
The term "oxidative stress" was first introduced in the eighties by Helmut Sies (1985), defin‐
ing it as a disturbance in the prooxidant-oxidant balance in favor of the first. From that time,
a great number of researchers have studied this phenomenon; so, the concept has evolved
and now, has been defined as “A situation when steady-state ROS concentration is transi‐
ently or chronically enhanced, disturbing cellular metabolism and its regulation and damag‐
ing cellular constituents” [5,6].
However, oxidative stress is a phenomenon not entirely detrimental for the organism; also,
free radicals (FR) have an important function in several homeostatic processes. They act as
intermediate agents in essential oxidation-reduction (redox) reactions. Some examples are
the destruction of microorganisms through phagocytosis, synthesis of inflammatory media‐
tors and detoxification. Therefore, FR in low concentrations are useful and even essential [7].
FR represents any chemical species that exists independently and has one or more unmatch‐
ed (odd) electrons rotating in its external atomic orbits. This highly unstable configuration
causes this chemical species to be very aggressive and to have a short life span. Once gener‐
ated, FR interact with other molecules through redox reactions to obtain a stable electronic
configuration [8-10].
Several authors have classified FR according to the functional group in their molecule, being
the most frequent the reactive oxygen species (ROS) and reactive nitrogen species (RNS).
Thiol radicals are less important, their reactive group contains sulfur; well as those contain‐
ing carbon or phosphorus in their reactive center. ROS are constituted by superoxide anion
(O2•−), hydroxyl radical (•OH), hydrogen peroxide (H2O2), and singlet oxygen. While, that
the RNS are nitric oxide (NO), nitrogen dioxide (NO2•−) and peroxynitrite (OONO−) [11,12].
Due to the constant production of ROS and RNS during metabolic processes, the organism
has developed a powerful, complex defense system that limits its exposure to these agents
these are the so-called antioxidants (AO). Several antioxidants are enzymes or essential nu‐
trients, or include these in their molecular structure. An essential nutrient is a compound
that must be eaten because the organism is unable to synthesize it. Based on this characteris‐
tic, some authors classify AO as non-enzymatic and enzymatic [12-14].
2.1. Enzimatic antioxidants
Some researchers state that the AO function performed by enzymes has advantages com‐
pared to AO compounds, for this activity is regulated according to cellular requirements:
they can be induced, inhibited or activated by endogenous effectors [15]. Ho and colleagues
(1998) showed evidence of the importance of AO enzymes in protection against oxidant
agents. When using transgenic mice designed to overexpress the activity of some AO en‐
zymes, it was noticed that there is a notorious tolerance of certain tissues when they are ex‐
posed to toxics and pathologic conditions that would promote ROS action [9,16].
Enzymatic AO catalyze electron transference from a substrate towards FR. Later, the sub‐
strates or reducing agents used in these reactions are regenerated to be used again, they ach‐
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ieve this by using the NADPH produced in different metabolic pathways [14]. A prolonged
exposure to ROS can result in diminished NADPH concentration, which is needed in other
important physiologic processes, even though some enzymatic AO do not consume cofac‐
tors. Superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) be‐
long to this group [12,14,17].
2.2. Non-enzymatic antioxidants
Non-enzymatic antioxidants constitute a heterogeneous group of hydrophobic and hydro‐
philic molecules that trap FR and create chemical species that are less noxious to cell integri‐
ty [18]. Essentially, they give an electron to a FR to stabilize it. Hydrophilic non-enzymatic
antioxidants are located mainly in the cytosol, mitochondrial and nuclear matrixes and in
extracellular fluids. They are vitamin C, glutathione, uric acid, ergothioneine and polyphe‐
nolic flavonoids [9,18].
3. Role of oxidative stress in the development and pathogenesis of the
chronic degenerative diseases
Currently, studies related to reactive oxygen species (ROS) and reactive nitrogen species
(RNS) have become a relevant issue in research with the main purpose of understanding
their functions and effects in the organism. Studies developed throughout the 20th century
have explained the action mechanisms of ROS and the operation of the systems responsible
for their elimination. These evidences have shown the existence of enzyme systems that pro‐
duce ROS (cytochrome P450, xanthine oxidase, respiratory chain) of the Fenton reaction, cat‐
alase, peroxidase, and superoxide dismutase [19].
All researches lead to the same conclusions so far: a) the evidence that the cells have special‐
ized systems to convert ROS into less reactive compounds, and b) if those systems would
fail, the ROS could be preexisting compounds for the development of diseases. Thus, several
researchers agree in the relevance of “oxidative stress” in medical problems, specifically in
pathogenesis and/or complications of chronic degenerative diseases [9,12,20,21].
Different observations suggest that these pathologies could be originated when reactive spe‐
cies are formed and suffer alterations, or when they are eliminated, or both. However, the
situation is real and much more complicated, for it is difficult to determine the crucial event
that originates this disease due to the diversity of forms of oxidative stress (Figure 1). Differ‐
ent researches indicate that mutations produced in genes are responsible of the metabolic
unbalance of ROS, while others suggest that environmental changes and common habits
weigh on human metabolic processes. However, doubt remains, if oxidative stress is the pri‐
mary event that leads to the disease or the oxidative phenomenon is developed throughout
the disease [22].
Whatever the means by which oxidative stress is induced and pathology is developed, the
majority of evidences coincide in the relevance of alterations or enzyme deficiencies. These
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deficiencies are often caused by mutations in genes coding antioxidant or related enzymes,
for example, by genetic polymorphism.
This concept is frequently related to large number of pathologies. Enzymes involved in de‐
fence against ROS are not an exception. All enzymes contributing to antioxidant defence can
be classified to really antioxidant ones, dealing directly with ROS as substrates, and auxili‐
ary ones. The latter enzymes respond for reparation or degradation of oxidatively modified
molecules, maturation and posttranslational modification of antioxidant enzymes and me‐
tabolism of low molecular mass antioxidants. As a rule, genetic polymorphisms of enzymes
may lead to oxidative stress and consequent diseases, among which cancer, neurodegenera‐
tion, cardiovascular disorders, and diabetes are most frequently mentioned. Among the
most studied enzymes with genetic polymorphism is the glucose-6-phosphate dehydrogen‐
ase, catalase, superoxide dismutase, glutathione peroxidase and those involved in repara‐
tion of oxidized molecules and the disease progression [22].
3.1. Glucose-6-phosphate dehydrogenase deficiency
The most striking example among polymorphisms of genes coding enzymes related to anti‐
oxidant defence is well-known deficiency in glucose-6-phosphate dehydrogenase (G6PDH)
which leads to favism; genetic disease characterized by the lysis of erythrocytes when con‐
sumed broad beans and other substances which are harmless to the general population [23].
Other pathologies which are related to the same deficiency are diabetes [24,25], vascular dis‐
eases [24], and cancer [26]. In these cases, oxidative stress is induced in specific cells; it was
shown that GSH may react with superoxide anion radical providing partial defence against
this ROS [27]. When decreasing GSH concentration in G6PDH-deficient individuals enhan‐
ces their sensitivity to redox-active compounds, producing superoxide. Superoxide is able to
react also with nitric oxide, leading to the formation of rather harmful oxidant peroxynitrite.
However, relation of this reaction to diabetes and vascular diseases is not because of peroxy‐
nitrite production and subsequent oxidative damage, but rather because of decrease in nitric
oxide level [28].
The latter is an important second messenger in certain signalling pathways particularly re‐
lated to vasodilation [29]. There is some probability also that individuals with G6PDH-defi‐
ciency may fail to regulate properly blood pressure [30]. Despite possible impairment in
nitric oxide production, there is also other way to connect G6PDH deficiency with vascular
diseases. It is known, that development of vascular diseases depends on the levels of homo‐
cysteine and folate, intermediates in metabolism of sulfur-containing amino acids [31]. Pro‐
duction of two these metabolites depends on GSH and NADPH levels in cells [32].
Data regarding association of G6PDH deficiency with cancer are controversial, because
some studies demonstrated that G6PDH-deficient patients may additionally suffer from
cancer [33], while others state opposite [34]. Nevertheless, both situations are possible. In
particular, there is a large data body indicating that different cancer types are developed at
increased DNA damage. It often happens under polymorphism in enzymes contributing to
DNA repair, what will be discussed below.
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Figure 1. Scheme of the different ways that produce oxidative stress and stimulate the development of chronic de‐
generative diseases. Abbreviations: ROS – reactive oxygen species, RNS – reactive nitrogen species, SOD – superoxide
dismutase, CAT - catalase, GSH-Px – glutathione-peroxidase, Prx - peroxyredoxin, GSH – reduced glutathione, CoQH2 –
ubiquinol.
On the other hand, NADPH supply at certain conditions may be even harmful leading to
enhanced oxidative damage and cancer development. Indeed, it was shown that G6PDH
was particularly responsible for cell growth and frequently correlated with cell growth [26].
Tian and colleagues (1998) found that cancer cells possessed several times higher G6PDH
activity. The positive correlation between tumour progression and G6PDH activity was
found also for humans [35,36].
Increased NADPH supply resulting from G6PDH overexpression can lead to so-called “re‐
ductive stress” [37]. Enhanced activity of G6PDH, a lipogenic enzyme, was found at diabe‐
tes and obesity [38]. In humans, G6PDH is regulated by many transcription factors, in
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particular, SREBP-1a (sterol regulatory element binding protein) [39], AP-1 [40] and Sp1
[41]. It was shown that elevation of G6PDH activity might lead to enhanced lipid synthesis
[42] and to possible reductive stress [43].
3.2. Catalase deficiency
The first case of catalase deficiency was described by Shigeo Takahara (1947) in a child with
cold sores and called acatalasemia to the patology [44]. The cause of this patology is related
to ability of oral Streptococci to produce hydrogen peroxide which may promote death of
mouth mucosa cells in acatalasemic patients [45]. Catalase deficiency is also associated with
diabetes mellitus [46]. This association is attributed for Hungarian hypocatalasemic patients.
They were shown to possess higher levels of homocysteine and lower levels of folate [32]. It
hints, on one hand, to abnormalities of sulfur metabolism, but on the other hand, it is com‐
monly known that higher homocysteine levels are related to cardiovascular diseases [47],
the fact we mentioned above in the context of G6PDH deficiency.
3.3. Polymorphism of Cu,Zn-SOD and protein aggregation
In recent years, the main attention has focused on the polymorphism of genes coding the
enzyme superoxide dismutase. More than 100 nucleotide substitutions for the gene SOD1
coding human cytosolic copper- and zinc containing SOD (Cu,Zn-SOD) were described [48].
It is known that several mutations in SOD1 gene are associated with cases of familial amyo‐
trophic lateral sclerosis (ALS), a neurodegenerative disease which is characterized by para‐
lysis and subsequent death [49]. Mechanisms of the disease development are still unknown,
but there are many evidences that oxidative stress, developed in neurons, is rather caused
by unexpected pro-oxidative activity of SOD than by the loss of the activity at all [50]. It was
found that the aggregates cause harm to the cells not only via oxidative stress, but also via
inhibition of glutamate receptors [51] and induction of apoptosis [52].
Irwin Fridovich presented some examples of unusual activities of SOD, such as oxidase-like
or reductase-like ones [53]. His works and data of other authors suggest that SOD, being
mutated or placed in specific conditions, may produce more harmful ROS tan hydrogen per‐
oxide, i.e. hydroxyl radical [54, 55]. Some studies suggested that SOD aggregation can be
triggered by higher susceptibility to oxidation of mutated protein [56,57]. Indeed, Cu,Zn-
SOD is considered to be rather stable, resistant to many, deleterious to other proteins, com‐
pounds [48]. These evidences suggest that Alzheimer, Huntington, and Parkinson diseases
are other pathologies related to this enzymatic alteration [22].
3.4. Polymorphism of Mn-SOD, extracellular SOD and glutathione peroxidase
Unlike Cu,Zn-SOD, less mutations were found in the gene coding human manganese con‐
taining superoxide dismutase (SOD2). Substitution of alanine-16 to valine (so called “Ala
variant”) is the most known mutation [58]. This mutation has recently been associated with
cancers of breast, prostate, ovaries and bladder, as well as non-Hodgkin lymphoma, meso‐
thelioma and hepatic carcinoma [58]. Mammals possess also extracellular Cu,Zn-SOD (EC-
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SOD) encoded in humans by gene SOD3. The enzyme is a homotetramer presenting in
plasma, lymph, and synovial fluid [59]. Extracellular SOD is abundant particularly in the
lung, blood vessels, and the heart. Consequently, polymorphism of SOD3 gene is associated
with pulmonary and cardiovascular diseases [60].
Polymorphism of glutathione peroxidase (GSH-Px) was found to be associated with some
cancers. Four GSH-Px isoforms have been described in humans. It was found that mutations
in exon 1 of human GSH-Px-1 gene lead to appearance of polyalanine tract at N-terminus of
the protein [59]. These tracts themselves are not connected with diminished enzyme activity.
Another polymorphism, substitution of proline-198 to leucine, was found in Japanese dia‐
betic patients and associated with intima-media thickness of carotid arteries [61]. The same
substitution for adjacent proline-197 was associated with lung and breast cancers, as well as
with cardiovascular diseases [59].
3.5. Polymorphism of enzymes involved in reparation of oxidized molecules
Mutations may also affect enzymes involved in DNA reparation. The enzyme 8-hydroxy-2′-
deoxyguanosine glycosylase (hOGG) encoded in human genome by the gene hOGG1 is
probably the most known example. Recent studies associate mutations in hOGG1 with dif‐
ferent cancer types, such as lung, stomach and bladder cancers [62]. Most of the mutations
in this gene affect exon 7 and cause serine-to-cysteine substitution. It was demonstrated that
substitution S326C in hOGG1 protein confers susceptibility to oxidation and makes the en‐
zyme prone to form disulfide bond between different polypeptide chains [63].
Hydrolase MTH1 is other important enzyme preventing incorporation of oxidized purine
nucleotide triphosphates in DNA [64]. Knockout of this enzyme in mice resulted in in‐
creased frequency of lung, stomach and liver tumours with age [65].
Other important antioxidant enzymes are glutathione S-transferases (GSTs). Its main function
is to conjugation of different electrophilic compounds with glutathione [66]. Oxidatively modi‐
fied compounds as well as lipid oxidation products, like 4-hydroxy-2-nonenal, are subjected to
conjugation with glutathione. In general, GSTs are belong to xenobiotic-elimitating system.
Some of them, namely GSTs of µ class, are known well by their ability to eliminate polycyclic ar‐
omatic hydrocarbons, oxidized previously by cytochrome P450 monooxygenases. To date,
eight classes of GSTs have been described: α, κ, µ,σ, ξ, π, θ, and ω. Cytosolic enzymes belong to
classes α, µ, π and θ [67]. The gene coding GSTM1 (GST of µ class, isoform 1) is appeared to be
highly polymorphic and found inactivated in half of human population.
Some studies associate polymorphism of GSTM1 with lung cancer [59,68], although reports
are controversial. For example, meta-analysis conducted by [69] found no association of
GSTM1 null genotype with lung cancers as well as with smoking. Other authors found such
association and reported increased susceptibility to cancerogens among Caucasian and Afri‐
can-American populations [70]. Polymorphism of GSTM1 was also found to be associated
with head and neck carcinomas [67]. The need in GSTM1 and its role in prevention of lung
cancer are explained by the ability of the enzyme to detoxify constituents of cigarette smoke,
such as mentioned above polycyclic aromatic hydrocarbons. Some studies also associate
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lung cancer with polymorphism of GSTT1 (GST of θ class) which participates in catabolism
of tobacco smoke constituents, such as halomethanes and butadione [70].
3.6. Role of oxidative modifications of antioxidant and related enzymes in disease
progression
Many disorders related to the metabolism of transition metals, amino acids or low molecular
mass reductants are known to be connected with activities of antioxidant enzymes. Particu‐
larly, impairement in selenium uptake or synthesis of selenocysteine needed for glutathione
peroxidase may lead to GSH-Px deficiency and subsequent disorders such as cardiovascular
ones [47]. Disruption of iron-sulfur clusters by superoxide anion radicals or peroxynitrite
leads frequently to impairment of many metabolic pathways. Indeed, aconitase, NADH-
ubiquinone-oxidoreductase (complex I of mitochondrial electron transport chain), ubiqui‐
nol-cytochrome c oxidoreductase (complex III), ribonucleotide reductase, ferredoxins
possess iron-sulfur clusters, susceptible to oxidation. Owing to this, aconitase is used as one
of oxidative stress markers [71]. On the other hand, iron is a component of haem, a prosthet‐
ic group in catalase holoenzyme. Susceptibility to oxidative modification is described for
catalase, glutathione peroxidase, Cu,Zn-SOD, and G6PDH. The latter is believed to be one of
the most susceptible to oxidation enzymes [22]. Thus, oxidative stress induced by exogenous
factors, like carcinogens, certain drugs, ions of transition metals, etc., or by metabolic disor‐
ders, like diabetes, can be exacerbated by oxidative modification of antioxidant enzymes.
These assumptions demonstrate the potential of antioxidant therapy in particular cases. At
some pathological states, whatever the cause of the disease, oxidative stress is seen to be a
powerful exacerbating factor. Type II diabetes, cardiovascular diseases and neurodegenera‐
tive diseases, associated with protein aggregation are among such pathologies. Indeed, en‐
hanced level of glucose results in higher probability of protein glycation [72].
4. Impact of chemopreventive agents in the chronic degenerative diseases
The available evidences indicates that individuals with chronic degenerative diseases are
more susceptible to oxidative stress and damage because they have elevated levels of oxi‐
dants and/or reduced antioxidants. Therefore, it has been posited that antioxidant supple‐
mentation  in  such  individuals  may  be  beneficial.  Different  research  has  confirmed that
many  common  foods  contain  nonnutritive  components  that  may  provide  protection
against chronic degenerative diseases, however, the most studies have had impact on the
cancer [20,21].
The "chemoprevention" seeks to eliminate precancerous cells in order to avoid the necessity
of chemotherapy. It can be further classified as primary, secondary, or tertiary prevention.
Primary chemoprevention focuses on preventing the development of precancerous lesions,
secondary chemoprevention focuses on preventing the progression of these lesions to can‐
cer, and tertiary chemoprevention aims to prevent the recurrence or spread of a primary
cancer [73].
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It has been known for some time that dietary factors play a role in the development of some
human cancers [73,74] and that some foods contain mutagens and carcinogens [74,75]. In‐
vestigations of last decades, has focused on the existence of a number of non nutritional
components in our regular diet that possess antimutagenic and anticarcinogenic properties,
these compounds have been called as chemopreventers [76,77].
The chemopreventers are classified as food entities that can prevent the appearance of some
long-term diseases like cancer or cardiovascular disorders. It has been suggested that che‐
moprevention should be considered as an inexpensive, easily applicable approach to cancer
control and "may become a major weapon in the anticancer arsenal" [76,78,79]. These com‐
pounds can be found in all food categories, but mainly in fruits, vegetables, grains and tea
[78,79]. Chemopreventers belong to different classes of chemicals but the most recognized
are some vitamins, food polyphenols, flavonoids, catechins, and some components in spices
[78, 79].
The mechanisms of action of the chemopreventers are complex and can be categorized ac‐
cording to the site of action or by the specific type of action. It appears that most chemo‐
preventers act primarily as antioxidants. As such, they may scavenge free radicals formed
during the preparation of food or as a normal biological process in the body. Recall, that the
free radicals can react with DNA, lipids, or cell membranes, leading to aging, injuries of the
organ, and greater susceptibility to develop the chronic degenerative disease. Therefore, any
event that removes free radicals in the human body is considered beneficial for human
health. In addition to their antioxidative activities, there are other mechanisms that show in
the Table 2 [80-82].
5. Chemopreventive evidence of some fruits and food supplements
evaluated by our research group
5.1. Cactus pears
Plants from the genus Opuntia are the most abundant of the Cactaceae family, grown
throughout the Americas as well as the central area of the Mediterranean, Europe, Asia, Af‐
rica, and Australia. Opuntia species display flattened stems called “pencas” or cladodes. The
cactus pear (also called prickly pears) is the fruit of this plant (Opuntia spp.). The fruit is an
oval berry with a large number of seeds and a semi-hard rind with thorns, which may be
grouped by fruit colors: red, purple, orange-yellow and white. The fruits with white pulp
and green rind are preferred for consumption as food, and their domestic production corre‐
sponds to almost 95% of the total production. Mexico is the main producer of cactus pears
and accounts for more than 45% of the worldwide production; however, only 1.5% of this
production is exported [83,84].
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Mechanism Action Examples
Inhibition of
carcinogen
formation
Agents that block or inhibit to the enzymes responsible for the
biotransformation of procarcinogens to carcinogen form
Dithiocarbamates,
isothiocyanates, diallyl
sulfide, and ellagic acid
Inducing agents Agents that induce or enhance enzyme activity (e.g.,
glutathione S-transferase, GST) for detoxify and reduce the
level of mutagenic/carcinogenic species of the body
Isothiocyanates,
sulfaraphane, d-limonene,
terpinoids, turmeric, and
curcurains
Suppressing agents Agents that may react on different processes (e.g., inhibition of
arachidonic acid metabolism, activity of protease or protein
kinase C) involved in tumor promotion/progression
isoflavones, phytoestrogens,
selenium
Immune activity
and modulation
Since the immune system can influence on growth either via
effects on the inflammation status or by causing apoptosis.
Some chemopreventers can act on the early stages in neoplasia
or have effects on frank malignancies
Carotenoid, flavonoids,
lactoferrin
Signal transduction
pathways and their
regulation
Some chemopreventers may alter signaling pathways of
receptors for hormones and others factors responsible for cell
regulation and can be modified the potential for growth,
either by acting to increase mitosis or alter the level of
apoptosis.
d-limonene, sulfur
compounds, lactoferrin,
retinoids
Table 2. Other mechanisms of chemoprevention
A viable strategy to increase the competitiveness of the Mexican cactus pear in national and
international markets is the innovation and creation of new high value-added products. This
could be achieved by determining the nutritional and functional properties that differentiate
the Mexican cactus pear from analogous products. In addition, providing functional prod‐
ucts for a market in constant growth would offer a key competitive advantage and would
allow the producers to diversify its commercialization, not as fresh fruit only, but also as an
ingredient or high-value additive for the food industry. A commercialization of the cactus-
pear based on its antioxidant properties could generate competitive advantages that may
turn into business opportunities and the development of new products [85].
Different studies with the varieties of European and Asian cactus pears have shown notable
antioxidant activities that significantly reduce oxidative stress in patients and may help in
preventing chronic pathologies (as diabetes and cancer) [85-87]. For this reason, the cactus
pear is considered a functional food; this feature is attributed to its bioactive compounds
such as vitamin C and vitamin E, polyphenols, carotenoids, flavonoid compounds (e.g.,
kaempferol, quercetin, and isorhamnetin), taurine and pigments [88,89].
Betalains are water-soluble pigments. Two betalain derivatives are present in cactus-pears:
betacyanin, which gives the red-purple color, and betaxanthin, which gives a yellow-orange
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color. These pigments have shown beneficial effects on the redox-regulated pathways in‐
volved in cell growth and inflammation, and have not shown toxic effects in humans [90,91].
In addition, a neuroprotector activity against oxidative damage induced in cultures of rat
cortical cells has been attributed to the cactus pear flavonoids [92]. Another beneficial effect
of the fruit was observed in the prevention of stomach ulcers through the stimulation of
prostaglandin production: cactus pear promoted mucous secretion of bicarbonate, involved
in the protection of gastric mucosa [93]. On the other hand, their contents of natural antioxi‐
dants has raised interest in the use of cactus pears as substitute for synthetic antioxidants,
such as butylhydroxytoluene (BHT), butylhydroxyanisole (BHA) [88].
In the Institute of Health Sciences (Autonomous University of Hidalgo State) have been per‐
formed studies to demostrate the chemopreventive capacity of the cactus pear. The first
studies were developed by Hernández-Ceruelos et al. (2009) with the main objective to eval‐
uate the antioxidant effect of three varieties of prickly pear juice (red-purple, white-green
and yellow-orange) in four different concentrations (25, 50, 75 and 100%) by the technique of
DPPH (1,1-diphenyl-2-picrylhydrazyl). Their results indicated that the juice of princkly pear
variety red-purple (PPRP) had the highest antioxidant capacity in all concentrations in com‐
parison with the positive control (vitamin E). Subsequently, researchers evaluated the anti‐
clastogenic potential of PPRP by micronucleus assay against of methyl methane sulfonate
(MMS) in mice. This experiment had a duration of 2 weeks, was included a negative control
(animals treated with water), a positive control of MMS (40 mg/kg), a group of mice treated
with princkly pear variety red-purple (25mL/Kg), and three groups with PPRP (in doses of
25, 16.5 and 8.3 mL/Kg) plus the mutagen. The PPRP was administered by oral gavage and
the mutagen was injected intraperitoneally 5 days before the end of the experiment (single
dose). Finally, blood samples were obtained in four times (0, 24, 48 and 72 hours) to deter‐
mine the frequency of micronucleated polychromatic erythrocytes (MNPE). The result indi‐
cated that PPRP is not a genotoxic agent, on the contrary, may reduce the number of
micronucleated polychromatic erythrocytes. In this regard, the princkly pear variety red-
purple showed an anticlastogenic effect directly proportional to the concentrations. The
highest protection was obtained with the concentration of 25 mL/Kg (approximately, 80%)
after 48 hours of treatment [94].
In the second study was evaluated the antioxidant activities [with three assays: a)1,1-di‐
phenyl-2-picrylhydrazyl radical-scavenging, b) protection against oxidation of a β-carotene-
linoleic acid emulsion, and c) iron(II) chelation], the content of total phenolic compounds,
ascorbic acid, betacyanin, betaxanthins and the stability of betacyanin pigments in presence
of Cu(II)-dependent hydroxyl radicals (OH•), in 18 cultivars of purple, red, yellow and
white cactus pear from six Mexican states (Hidalgo, Puebla, Guanajuato, Jalisco, Zacatecas
and the State of Mexico). The results indicated that the antiradical activities from yellow and
white cactus pear cultivars were not significantly different and were lower than the average
antiradical activities in red and purple cultivars. The red cactus pear from the state of Zaca‐
tecas showed the highest antioxidant activity. The free radical scavenging activity for red
cactus pears was significantly correlated to the concentration of total phenolic compounds
(R2 = 0.90) and ascorbic acid (R2 = 0.86). All 18 cultivars of cactus pears studied showed sig‐
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nificant chelating activity of ferrous ions. The red and purple cactus pears showed a great
stability when exposed to OH• [88].
5.2. Cranberries
Among small soft-fleshed colorful fruits, berries make up the largest proportion consumed
in our diet. Berry fruits are popularly consumed not only in fresh and frozen forms, but also
as processed and derived products including canned fruits, yogurts, beverages, jams, and
jellies. In addition, there has been a growing trend in the intake of berry extracts as ingredi‐
ents in functional foods and dietary supplements, which may or may not be combined with
other colorful fruits, vegetables, and herbal extracts [95]. Berry fruits commonly consumed
in America include blackberries, black raspberries, red raspberries and strawberries, blue‐
berries, and cranberries.
Other “niche-cultivated” berries and forest/wild berries, for example, bilberries, black cur‐
rant, lingonberry, and cloudberry, are also popularly consumed in other regions of the
World [95]. The North American cranberry (Vaccinium macrocarpon) is of a growing public
interest as a functional food because of potential health benefits linked to phytochemicals of
the fruit. Cranberry juice has long been consumed for the prevention of urinary tract infec‐
tions, and research linked this property to the ability of cranberry proanthocyanidins to in‐
hibit the adhesion of Escherichia coli bacteria responsible for these infections [96]. These
studies, which brought to light the unique structural features of cranberry proanthocyani‐
dins [97], have sparked numerous clinical studies probing a cranberry´s role in the preven‐
tion of urinary tract infections and targeted the nature of the active metabolites. Further
antibacterial adhesion studies demonstrated that cranberry constituents also inhibit the ad‐
hesion of Helicobacter pylori, a major cause of gastric cancer, to human gastric mucus [98].
The earliest report of potential anti-carcinogenic activity appeared in 1996 in the University
of Illinois [99].
Extracts of cranberry and bilberry were observed to inhibit ornithine decarboxylase (ODC)
expression and induce the xenobiotic detoxification enzyme quinonereductase in vitro [99].
Subsequent studies with cranberry and other berries in cellular models have focused on
some cancers such as breast, colon, liver, prostate and lung [100-102]. This biological activity
of berries are partially attributed to their high content of a diverse range of phytochemicals
such as flavonoids (anthocyanins, flavonols, and flavanols), tannins (proanthocyanidins, el‐
lagitannins, and gallotannins), quercetin, phenolic acids, lignans, and stilbenoids (e.g., re‐
sveratrol) [100]. With respect to his genotoxic and/or antigenotoxic potential, there are few
reports in the literature that demonstrate this effect and the majority of studies were per‐
formed in vitro cell culture models [101,103,104]. Boateng et al. demonstrated that consump‐
tion of some juices of berries (as blueberries, blackberries, and cranberry) can reduce the
formation of aberrant crypt foci (ACF) induced by azoxymethane in Fisher male rats [105].
Another study, in which it was administrated a lyophilized extract of Vaccinium ashei berries
in male Swiss mice during 30 days, showed to have improved the performance on memory
tasks and has a protective effect on the DNA damage in brain tissue evaluated with the com‐
et assay [106].
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Although the types of berry fruits consumed worldwide are many, the experiment executed
in our laboratory is focuses on cranberries that are commonly consumed in Mexico, especial‐
ly in the states of Tlaxcala, Hidalgo, and Puebla. The purpose of our study was to determine
whether cranberry ethanolic extract (CEE) can prevent the DNA damage produced by ben‐
zo[a]pyrene (B[a]P) using an in vivo mouse peripheral blood micronucleus assay. The exper‐
imental groups were organized as follows: a negative control group (without treatment), a
positive group treated with B[a]P (200 mg/kg), a group administered with 800 mg/kg of
cranberry ethanolic extract, and three groups treated with B[a]P and cranberry ethanolic ex‐
tract (200, 400, and 800 mg/kg) respectively. The CEE and benzo[a]pyrene were adminis‐
tered orally for a week, on a daily basis. During this period the body weight, the feed intake,
and the determination of antigenotoxic potential were quantified. At the end of this period,
we continued with the same determinations for one week more (recovery period) but any‐
more administration of the substances. The animals treated with B[a]P showed a weight in‐
crease after the first week of administration. The same phenomenon was observed in the lots
combined with B[a]P and CEE (low and medium doses). The dose of 800 mg/kg of CEE
showed similar values to the control group at the end of the treatment period. In the second
part of the assay, when the substances were not administered, these experimental groups re‐
gained their normal weight. The dose of CEE (800 mg/kg) was not genotoxic nor cytotoxic.
On the contrary, the B[a]P increases the frequency of micronucleated normochromatic eryth‐
rocytes (MNNE) and reduces the rate of polychromatic erythrocytes (PE) at the end of the
treatment period. With respect to the combined lots, a significant decrease in the MN rate
was observed from the sixth to the eighth day of treatment with the two high doses applied;
the highest protection (60%) was obtained with 800 mg/kg of CEE. The same dose showed
an anticytotoxic effect which corresponded to an improvement of 62.5% in relation to the an‐
imals administered with the B[a]P. In the second period, all groups reached values that have
been seen in the control group animals. Our results suggest that the inhibition of clastoge‐
nicity of the cranberry ethanolic extract against B[a]P is related to the antioxidant capacity of
the combination of phytochemicals present in its chemical composition [107].
5.3. Grapefruit juice and naringin
The grapefruit is a subtropical citrus tree known for its bitter fruit. These evergreen trees
usually grow around 6 meters tall. The leaves are dark green, long and thin. His fruit (called
toronja in Spanish) has become popular since the late 19th century, is yellow-orange skinned
and largely an oblate spheroid and generally, is consumed in form of juice [108].
The grapefruit juice is an excellent source of many nutrients and phytochemicals that con‐
tribute to a healthy diet. Is a good source of vitamin C, contains the fiber pectin, and the va‐
rieties pink and red contain the beneficial antioxidant lycopene [108]. But, the main
flavonoid, existing in highest concentration in grapefruit juice is naringin, which in humans
is metabolized to naringenin [109].
Since grapefruit juice is known to inhibit enzymes necessary for the clearance of some drugs
and hormones, some researchers have hypothesized that grapefruit juice and the naringin
may play an indirect role in the development of hormone-dependent cancers. A study found
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a correlation between eating a quarter of grapefruit daily and a 30% increase in risk for
breast cancer in post-menopausal women. The study points to the inhibition of CYP3A4 en‐
zyme by grapefruit, which metabolizes estrogen [110]. However, an investigation conducted
in 2008 has shown that grapefruit consumption does not increase breast cancer risk and
found a significant decrease in breast cancer risk with greater intake of grapefruit in women
who never used hormone therapy [111].
In the case of naringin, this compound exerts a variety of pharmacological effects such as
antioxidant activity, blood lipid lowering, anticancer activity, and inhibition of selected
drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may
result in drug-drug interactions in vivo. Ingestion of naringin and related flavonoids can al‐
so affect the intestinal absorption of certain drugs, leading to either an increase or decrease
in circulating drug levels [112].
This evidence has motivated to our research group to develop various studies with grape‐
fruit juice (GJ) and the naringin (Nar) to assess his chemoprotective ability.
Our first experience was with naringin in 2001. On that occasion, the study was designed for
three main purposes: (1) to determine whether Nar has a genotoxic effect in mouse in vivo.
This was evaluated by measuring the rate of micronucleated polychromatic erythrocytes
(MNPE); (2) to determine its antigenotoxic and its anticytotoxic potential on the damage
produced by ifosfamide. The first study was done by scoring the rate of MNPE, and the sec‐
ond one by establishing the index polychromatic erythrocytes/normochromatic erythrocytes
(PE/NE); and (3) to explore whether its antigenotoxic mechanism of action is related to an
inhibitory effect of Nar on the expression of the CYP3A enzyme, an effect which could avoid
the biotransformation of ifosfamide.
A single oral administration was used for all groups in the experiment: three groups were
given different doses of Nar (50, 250, and 500 mg/kg), other groups received the same doses
of Nar plus an administration of ifosfamide (60 mg/kg), another group treated with distilled
water and another with ifosfamide (60 mg/kg) were used as negative and positive controls,
respectively. The micronuclei and the cell scoring were made in blood samples taken from
the tail of the animals at 0, 24, 48, 72, and 96 h. The results showed that Nar was neither
genotoxic nor cytotoxic with the doses tested, but ifosfamide produced an increase in the
rate of MNPE at 24 and 48 h. The highest value was 24+/-1.57 MNPE per thousand cells at 48
h. The index PE/NE was significantly reduced by ifosfamide at 24 and 48 h. Concerning the
antigenotoxic capacity of Nar, a significant decrease was observed in the MNPE produced
by ifosfamide at the three tested doses. This effect was dose-dependent, showing the highest
reduction in MNPE frequency (54.2%) at 48 h with 500 mg/kg of Nar. However, no protec‐
tion on the cytotoxicity produced by ifosfamide was observed. Immunoblot analysis was
used to assess the CYP3A expression in liver and intestinal microsomes from mouse ex‐
posed orally to Nar. An induction in the CYP3A protein was observed in both intestinal and
hepatic microsomes from treated mice. This induction correlated with an increase in eryth‐
romycin N-demethylase activity. These data suggest that other mechanism(s) are involved
in the antigenotoxic action of naringin [113].
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With regard to grapefruit juice (GJ), we performed two experiments which are summarized
below. The first evaluated the capacity of GJ to inhibit the micronucleated polychromatic er‐
ythrocytes (MNPE) produced by daunorubicin in an acute assay in mice, as well as to deter‐
mine its antioxidant potential in mouse hepatic microsomes, and its capacity to trap free
radicals in vitro.
The results showed that GJ is not toxic or genotoxic damage; on the contrary, it generated a
significant reduction of the MNPE formed by daunorubicin. The effect was found through‐
out the examined schedule (from 24 to 96 h). The two high doses produced inhibition of
about 60% at 48 h, 86% at 72 h and 100% at 96 h after the treatment. With respect to the
grapefruit juice antioxidant potential, a 50% decrease in liver microsomal lipid peroxidation
produced by daunorubicin was found by quantifying malondialdehyde formation. Finally, a
strong GJ scavenging activity evaluated with the 1,1-diphenyl-2-picryl-hydrazyl (DPPH)
was observed, giving rise to a concentration-dependent curve with a correlation coefficient
of 0.98. Overall, our results established an efficient anticlastogenic potential of grapefruit
juice, probably related to its antioxidant capacity, or to alterations of daunorubicin metabo‐
lism [114].
Based on this background; recently, we finished another study in which using the comet as‐
say was demonstrated a strong effect by hydrogen peroxide (HP) and no damage by grape‐
fruit juice (GJ) in human lymphocytes. Cells exposed to HP and treated with GJ was shown
an increase of DNA damage by HP over the control level, and a decrease of such damage by
GJ. With the comet assay plus formamidopyrimidine-DNA-glycosylase we found the stron‐
gest increase of DNA damage by HP over the control level, and the strongest reduction of
such damage by GJ. By applying the comet/FISH method we determined 98% of the p53
gene signals in the comet head of control cells along the experiment, in contrast with about
90% signals in the comet tail of cells exposed to HP. Cells treated with both agents showed a
significant, concentration/time dependent return of p53 signals to the head, suggesting en‐
hancement of the gene repair. Finally, with the annexin V assay we found an increase in
apoptosis and necrosis by HP, and no effect by GJ; when GJ was added to HP treated cells
no modification was observed in regard to apoptosis, although a decrease of necrosis was
observed [115].
5.4. Chamomile
Chamomile (Matricaria chamomilla or Chamomilla recutita) is an asteraceae plant native to Eu‐
rope and distributed around the world, except in tropical and polar regions. This plant has
been used for its curative properties since ancient Egyptian and Greek times, and at present
is frequently used as an antiseptic, antiflogistic, diuretic, expectorant, febrifuge, sedative, an‐
ti-inflammatory and anticarcinogen [116]. Pharmacological activities of various components
of the plant have been reported, for example, the anti-inflammatory capacity and the modu‐
lating effects of the heat shock protein on apigenin and quercetin flavonoids, as well as the
anti-inflammatory, antioxidant, and antiseptic activities detected on α-bisabolol, guargazu‐
lene, and chamazulene [117, 118]. The essential oil extracted from the chamomile flower var‐
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ies from 0.42 to 2%, and consists of compounds such as bisabolol, chamazulene, cyclic
sesquiterpenes, bisabolol oxides, and other azulenes and terpenes [119].
With respect to his genotoxic and/or antigenotoxic potential, there are few reports in the lit‐
erature that demonstrate this effect. Therefore, our laboratory performed two investigations
with the main purpose to evaluate the chemoprotection capacity of chamomile. Initially, we
obtained the chamomile essential oil (CEO) from flowers of Chamomilla recutita by steam dis‐
tillation, and then it was analyzed by gas chromatography to identify the chemical species.
Thirteen compounds were determined with this assay, including bisabolol and its oxides, β-
farnecene, chamazulene, germacrene, and sesquiterpenes (Table 3).
Compound RTa Area (%)
(E)-β-Farnecene 38.46 28.17
Germacrene-D 39.23 2.19
Unidentified sesquiterpene 40.07 1.40
Unidentified sesquiterpene 41.17 0.78
(Ζ,Ε)−α−Farnecene 41.35 1.59
Unidentifiedsesquiterpene 48.52 0.71
α−Bisabolol oxide A 54.46 41.77
α−Bisabolol oxide B 49.28 4.31
α-Bisabolol oxide 50.65 5.30
α−Bisabolol 51.18 2.31
Chamazulene 52.80 2.39
1,6-Dioxaspiro[4,4]non-3-ene,2-(2,4hexadyn-1-ylidene) 60.73 2.19
Hexatriacontane 67.49 0.50
RTa, Retention time obtained with gas chromatography.
Table 3. Components of the tested chamomile essential oil
The first work was to determine the inhibitory effect of the CEO, on the sister chromatid ex‐
changes (SCEs) produced by daunorubicin and methyl methanesulfonate (MMS) in mouse
bone marrow cells.
The authors performed a toxic and genotoxic assay of chamomile essential oil; both showed
negative results. To determine whether CEO can inhibit the mutagenic effects induced by
daunorubicin, one group of mice was administered corn oil, another group was treated with
the mutagen (10 mg/kg), a third group was treated with 500 mg/kg of CEO; three other
groups were treated first with CEO (5, 50 and 500 mg/kg) and then with 10 mg/kg of dau‐
norubicin. In the case of MMS, the experimental groups consisted of the following: the nega‐
tive control group which was administered corn oil, a group treated with 25 mg/kg of MMS,
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a group treated with 1000 mg/kg of CEO, and three groups treated first with CEO (250, 500
and 1000 mg/kg) and then with MMS (25 mg/kg). The results indicated a dose-dependent
inhibitory effect on the SCEs formed by both mutagens. In the case of daunorubicin, a statis‐
tically significant result was observed in the three tested doses: from the lowest to the high‐
est dose, the inhibitory values corresponded to 25.7, 63.1 and 75.5%. No alterations were
found with respect to the cellular proliferation kinetics, but a reduction in the mitotic index
was detected. As regards MMS, the inhibitory values were 24.8, 45.8 and 60.6%; no altera‐
tions were found in either the cellular proliferation kinetics or in the mitotic indices [120].
This results suggested that CEO may be an effective antimutagen and was the reason for de‐
velop the second study.
The aim of the second investigation was to determine the inhibitory potential of CEO on the
genotoxic damage produced by daunorubicin (DAU) in mice germ cells. We evaluated the
effect of 5, 50, and 500 mg/kg of essential oil on the rate of sister chromatid exchange (SCE)
induced in spermatogonia by 10 mg/kg of the mutagen. We found no genotoxicity of CEO,
but detected an inhibition of SCE after the damage induced by DAU; from the lowest to the
highest dose of CEO we found an inhibition of 47.5%, 61.9%, and 93.5%, respectively. As a
possible mechanism of action, the antioxidant capacity of CEO was determined using the
1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging method and ferric thiocya‐
nate assays. In the first test we observed a moderate scavenging potential of the oil; never‐
theless, the second assay showed an antioxidant capacity similar to that observed with
vitamin E. In conclusion, we found that CEO is an efficient chemoprotective agent against
the damage induced by DAU in the precursor cells of the germinal line of mice, and that its
antioxidant capacity may induce this effect [116].
5.5. Silymarin
Silybum marianum is the scientific name of milk thistle or St. Mary’s thistle. It is a Mediterra‐
nean native plant belonging to the Asteraceae family. It is characterized by thorny branches,
a milky sap, with oval leaves that reach up to 30 centimeters, its flowers are bright pink and
can measure up to 8 cm to diameter [121].
Milk  thistle  (Mt)  grows  of  wild  form in  the  southern  Europe,  the  northern  Africa  and
the  Middle  East  but  is  cultivated  in  Hungary,  China  and South  American  countries  as
Argentina,  Venezuela  and  Ecuador.  In  México,  is  consumed  as  supplement  food  for
many years ago [122].
In  the  sixties  years,  German scientists  performed a  chemical  investigation  of  his  fruits,
isolating  a  crude  extract  formed  by  active  compounds  with  hepatoprotective  capacity;
this  group of  compounds was called silymarin.  In 1975,  it  was found that  the principal
components of silymarin are silybin A, silybin B, isosilybin A, isosilybin B, silychristin A,
silychristin  B  and silydianin  [123].  Currently  it  is  known that  the  chemical  constituents
of  silymarin  are  flavonolignans,  ie,  a  combination conformed by flavonoids  and lignins
structures [124].
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Mt is one of the most investigated plant extracts with known mechanisms of action for oral
treatment of toxic liver damage. Silymarin is used as a protective treatment in acute and
chronic liver diseases [125]. His protective capacity is related with different mechanisms as
suppress toxin penetration into the hepatic cells, increasing superoxide dismutase activity,
increasing glutathione tissue level, inhibition of lipid peroxidation and enhancing hepato‐
cyte protein synthesis. The hepatoprotective activity of silymarin can be explained based on
antioxidant properties due to the phenolic nature of flavonolignans. It also acts through
stimulating liver cells regeneration and cell membrane stabilization to prevent hepatotoxic
agents from entering hepatocytes [126].
Silymarin is also beneficial for reducing the chances for developing certain cancers [127].
The molecular targets of silymarin for cancer prevention have been studied. Milk thistle in‐
terfere with the expressions of cell cycle regulators and proteins involved in apoptosis to
modulate the imbalance between cell survival and apoptosis. Sy-Cordero et al. (2010) isolat‐
ed four key flavonolign and diastereoisomers (silybin A, silybin B, isosilybin A and isosily‐
bin B) from S. marianum in gram scale. These compounds and other two related analogues,
present in extremely minute quantities, were evaluated for antiproliferative/cytotoxic activi‐
ty against human prostate cancer cell lines. Isosilybin B showed the most potent activity
[126]. The isolation of six isomers afforded a preliminary analysis of structure-activity rela‐
tionship toward prostate cancer prevention. The results suggested that an ortho relationship
for the hydroxyl and methoxy substituents in silybin A, silybin B, isosilybin A and isosilybin
B was more favorable than the meta relationship for the same substituents in the minor fla‐
vonolignans. Silymarin suppressed UVA-induced oxidative stress that can induce skin dam‐
age. Therefore, topical application of silymarin can be a useful strategy for protecting
against skin cancer [128].
In our laboratory, we evaluated the antigenotoxic effect of two doses of silymarin (200 and
400 mg/Kg) administered by oral gavage against the chronic consumption of ethanol (solu‐
tion: 92 mL of water/8 mL of ethanol) during a week with alkaline single cell electrophoresis
(comet) assay.
Figure 2 shows the comet measurements obtained in our assay. To summarize, at the 24
hours  of  the  schedule  we  found  no  significant  DNA  damage  induced  in  the  control
group (only water)  and the silymarin group (400 mg/kg),  both groups had a mean T/N
index of 1.1. On the contrary, the mice (strain CD-1) that consumed the solution of etha‐
nol  showed a  slight  comet  increase  during this  same time.  But  at  48,  72  and 96  hours,
this  group showed a  T/N index  increase  of  about  four  times  as  much.  During  the  last
times (120, 144, 168 and 192) there is a decrease of DNA damage, suggesting that hepa‐
tocytes  are  in  the  process  of  cell  regeneration.  With  respect  to  the  groups  treated  with
the combination of chemicals,  a clear antigenotoxic effect was found with the two doses
of  silymarin;  particularly  with  400  mg/kg,  the  prevention  of  DNA  damage  was  about
70%  during  the  48,  72,  96  and  120  hours  of  treatment.  At  the  end  of  the  experiment,
these groups reached similar values to the negative control [129].
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Figure 2. Antigenotoxic effect of silymarin (Sly) against the DNA damage induced by the chronic consumption of eta‐
nol (Et-OH). Results are the mean ± SD of 5 mice per group (100 nuclei per doses) a statistically significant difference
with respect to the value of the control group and, b with respect to the value obtained in mice treated with Et-OH
only. ANOVA and Student-Newman Keuls tests, p ≤ 0.05.
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